[Abstract] Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the evolution of the disease. The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, ...
Abstract Despite the proven success of hormonal therapy for prostate cancer using chemical or surgic...
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, wi...
Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is the main...
PURPOSE: To improve the outcomes of patients with castration-resistant prostate cancer (CRPC), there...
Advanced prostate cancer has been recognized as being responsive to androgen deprivation since the 1...
Sumanta Kumar Pal1, Przemyslaw Twardowski1, Oliver Sartor21Division of Genitourinary Malignancies, D...
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit...
BACKGROUND: Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel...
Taxane based chemotherapy is an effective treatment for castration-resistant prostate cancer (CRPC) ...
For decades, cytotoxic therapy was considered ineffective for the treatment of metastatic castration...
Introduction: Treatment options for patients with metastatic castration-resistant prostate cancer (m...
Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial ...
Abiraterone acetate is a novel irreversible inhibitor of CYP17 that was recently approved for men wi...
Background: Both taxanes, docetaxel and cabazitaxel, are effective treatments for metastatic castrat...
Chemotherapy of castration resistant prostate cancer (CRPC) is based on taxane formulations worldwid...
Abstract Despite the proven success of hormonal therapy for prostate cancer using chemical or surgic...
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, wi...
Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is the main...
PURPOSE: To improve the outcomes of patients with castration-resistant prostate cancer (CRPC), there...
Advanced prostate cancer has been recognized as being responsive to androgen deprivation since the 1...
Sumanta Kumar Pal1, Przemyslaw Twardowski1, Oliver Sartor21Division of Genitourinary Malignancies, D...
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit...
BACKGROUND: Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel...
Taxane based chemotherapy is an effective treatment for castration-resistant prostate cancer (CRPC) ...
For decades, cytotoxic therapy was considered ineffective for the treatment of metastatic castration...
Introduction: Treatment options for patients with metastatic castration-resistant prostate cancer (m...
Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial ...
Abiraterone acetate is a novel irreversible inhibitor of CYP17 that was recently approved for men wi...
Background: Both taxanes, docetaxel and cabazitaxel, are effective treatments for metastatic castrat...
Chemotherapy of castration resistant prostate cancer (CRPC) is based on taxane formulations worldwid...
Abstract Despite the proven success of hormonal therapy for prostate cancer using chemical or surgic...
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, wi...
Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is the main...